Antisense-mediated reduction in thrombospondin-1 expression reduces cell motility in malignant glioma cellsAMAGASAKI, Kenichi; SASAKI, Atsushi; KATO, Goro et al.International journal of cancer. 2001, Vol 94, Num 4, pp 508-512, issn 0020-7136Article

Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytesKONO, Koji; SATO, Eiji; NAGANUMA, Hirofumi et al.Clinical cancer research. 2004, Vol 10, Num 7, pp 2538-2544, issn 1078-0432, 7 p.Article

Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas : participation of nuclear factor-κB in upregulation of syndecan-1 expressionWATANABE, Arata; MABUCHI, Tadashi; SATOH, Eiji et al.Journal of neuro-oncology. 2006, Vol 77, Num 1, pp 25-32, issn 0167-594X, 8 p.Article

Cell density regulates thrombospondin-1 production in malignant glioma cellsNAGANUMA, Hirofumi; SATOH, Eiji; KAWATAKI, Tomoyuki et al.Journal of neuro-oncology. 2003, Vol 63, Num 2, pp 147-153, issn 0167-594X, 7 p.Article

Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-γ and -βSATOH, Eui; MABUCHI, Tadashi; SATOH, Hiroki et al.Journal of neurosurgery. 2006, Vol 104, Num 2, pp 264-271, issn 0022-3085, 8 p.Article

Quantification of thrombospondin-1 secretion and expression of αvβ3 and α3β1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cellsNAGANUMA, Hirofumi; SATOH, Eiji; ASAHARA, Takayuki et al.Journal of neuro-oncology. 2004, Vol 70, Num 3, pp 309-317, issn 0167-594X, 9 p.Article